nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

05.06.2018 | Original Article – Clinical Oncology

Trastuzumab-induced cardiotoxicity and its risk factors in real-world setting of breast cancer patients

verfasst von: Tiina Moilanen, Anna Jokimäki, Olli Tenhunen, Jussi P. Koivunen

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 8/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Cardiotoxicity is the most important side effect of trastuzumab treatment. Heart function monitoring is recommended during the treatment which has led to growing use of resources. The aim of this retrospective study was to determine the frequency and timing of trastuzumab cardiotoxicity and its risk factors in real-world setting.

Methods

Single institute, retrospective collection of data on HER2+ breast cancer patients (n = 246) was carried out through a pharmacy search for patients who had received trastuzumab in 2006–2014. Clinical and pathological factors, treatment history, EF measurements, cardiac medications, cardiovascular disease history, cardiac symptoms, and survival data were collected from patient records.

Results

32 patients (13%) had EF decline ≥ 10%, eleven (4.5%) had EF decline ≥ 20% within 1 year after trastuzumab initiation, and trastuzumab was discontinued due to suspected cardiotoxicity in six patients (2.4%). 49 patients (19.9%) experienced symptoms related to cardiotoxicity during therapy, which accumulated among those with EF drop. Underlying cardiovascular diseases and multiple (≥ 2) cardiac medications were related to EF drop (≥ 20%) and trastuzumab discontinuation. Majority of EF drops (≥ 10%) and trastuzumab discontinuations were seen within 6months of trastuzumab initiation and recovery of EF drop to < 10% of the baseline was seen in most cases (62.5%). There was no statistically significant difference in the survival of patients according to EF drop.

Conclusions

Trastuzumab cardiotoxicity seems to accumulate among patients with underlying cardiac conditions. EF monitoring could be targeted to risk groups without compromising of the cardiac health or survival of HER2-positive breast cancer patients.

Baron KB, Brown JR, Heiss BL, Marshall J, Tait N, Tkaczuk KHR et al (2014) Trastuzumab-induced cardiomyopathy: Incidence and associated risk factors in an inner-city population. J Card Fail 20(8):555–559. https://doi.org/10.1016/j.cardfail.2014.05.012 CrossRefPubMed

Baselga J, Cortés J, Kim S, Im S, Hegg R, Im Y et al (2012) Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366(2):109–119. https://doi.org/10.1056/NEJMoa1113216 CrossRefPubMed

Bowles EJA, Wellman R, Feigelson HS, Onitilo AA, Freedman AN, Delate T et al (2012) Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst 104(17):1293–1305. https://doi.org/10.1093/jnci/djs317 CrossRefPubMedPubMedCentral

Burstein HJ, Kuter I, Campos SM, Gelman RS, Tribou L, Parker LM et al (2001) Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 19(10):2722–2730. https://doi.org/10.1200/JCO.2001.19.10.2722 CrossRefPubMed

Cardinale D, Colombo A, Torrisi R, Sandri MT, Civelli M, Salvatici M et al (2010) Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol 28(25):3910–3916. https://doi.org/10.1200/JCO.2009.27.3615 CrossRefPubMed

Crone SA, Zhao Y, Fan L, Gu Y, Minamisawa S, Liu Y et al (2002) ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 8(5):459–465. https://doi.org/10.1038/nm0502-459 CrossRefPubMed

ElZarrad MK, Mukhopadhyay P, Mohan N, Hao E, Dokmanovic M, Hirsch DS et al (2013) Trastuzumab alters the expression of genes essential for cardiac function and induces ultrastructural changes of cardiomyocytes in mice. PLOS One 8(11):e79543. https://doi.org/10.1371/journal.pone.0079543 CrossRefPubMedPubMedCentral

FDA (2017) Trastuzumab prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/103792s5337lbl.pdf. Accessed 5 June 2018

Florido R, Smith KL, Cuomo KK, Russell SD (2017) Cardiotoxicity from human epidermal growth factor receptor-2 (HER2) targeted therapies. J Am Heart Assoc. https://doi.org/10.1161/JAHA.117.006915 PubMedPubMedCentralCrossRef

Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T et al (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355(26):2733–2743. https://doi.org/10.1056/NEJMoa064320 CrossRefPubMed

Goldhirsch A, Gelber RD, Piccart-Gebhart M, de Azambuja E, Procter M, Suter TM et al (2013) 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet 382(9897):1021–1028. https://doi.org/10.1016/S0140-6736(13)61094-6 CrossRefPubMed

Guarneri V, Lenihan DJ, Valero V, Durand J, Broglio K, Hess KR et al (2006) Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. anderson cancer center experience. J Clin Oncol 24(25):4107–4115. https://doi.org/10.1200/JCO.2005.04.9551 CrossRefPubMed

Guenancia C, Lefebvre A, Cardinale D, Yu AF, Ladoire S, Ghiringhelli F et al (2016) Obesity as a risk factor for anthracyclines and trastuzumab cardiotoxicity in breast cancer: a systematic review and meta-analysis. J Clin Oncol 34(26):3157–3165. https://doi.org/10.1200/JCO.2016.67.4846 CrossRefPubMedPubMedCentral

Joensuu H, Kellokumpu-Lehtinen P, Bono P, Alanko T, Kataja V, Asola R et al (2006) Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354(8):809–820. https://doi.org/10.1056/NEJMoa053028 CrossRefPubMed

Kaufman B, Mackey JR, Clemens MR, Bapsy PP, Vaid A, Wardley A et al (2009) Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2–Positive, hormone Receptor–Positive metastatic breast cancer: Results from the randomized phase III TAnDEM study. 27(33):5529–5537. https://doi.org/10.1200/JCO.2008.20.6847

Lee KF, Simon H, Chen H, Bates B, Hung MC, Hauser C (1995) Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 378(6555):394–398. https://doi.org/10.1038/378394a0 CrossRefPubMed

Moja L, Tagliabue L, Balduzzi S, Parmelli E, Pistotti V, Guarneri V et al (2012) Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD006243.pub2 CrossRefPubMed

Nemeth BT, Varga ZV, Wu WJ, Pacher P (2017) Trastuzumab cardiotoxicity: from clinical trials to experimental studies. Br J Pharmacol 174(21):3727–3748. https://doi.org/10.1111/bph.13643 CrossRefPubMed

Piccart-Gebhart M, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353(16):1659–1672. https://doi.org/10.1056/NEJMoa052306 CrossRefPubMed

Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353(16):1673–1684. https://doi.org/10.1056/NEJMoa052122 CrossRefPubMed

Seferina SC, de Boer M, Derksen MW, van dB, van Kampen R,JW, van de Wouw A,J et al (2016) Cardiotoxicity and cardiac monitoring during adjuvant trastuzumab in daily dutch practice: a study of the southeast Netherlands breast cancer consortium. Oncologist 21(5):555–562. https://doi.org/10.1634/theoncologist.2015-0230 CrossRefPubMedPubMedCentral

Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235(4785):177–182CrossRefPubMed

Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE et al (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244(4905):707–712CrossRefPubMed

Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344(11):783–792. https://doi.org/10.1056/NEJM200103153441101 CrossRefPubMed

Swain SM, Baselga J, Kim S, Ro J, Semiglazov V, Campone M et al (2015) Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 372(8):724–734. https://doi.org/10.1056/NEJMoa1413513 CrossRefPubMedPubMedCentral

Telli ML, Hunt SA, Carlson RW, Guardino AE (2007) Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. 25(23):3525–3533. https://doi.org/10.1200/JCO.2007.11.0106

Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J et al (2012) Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367(19):1783–1791. https://doi.org/10.1056/NEJMoa1209124 CrossRefPubMedPubMedCentral

von Minckwitz G, du Bois A, Schmidt M, Maass N, Cufer T, de Jongh FE et al (2009) Trastuzumab beyond progression in human epidermal growth factor receptor 2–Positive advanced breast cancer: A german breast group 26/breast international group 03–05 study. 27(12):1999–2006. https://doi.org/10.1200/JCO.2008.19.6618

Yu AF, Yadav NU, Lung BY, Eaton AA, Thaler HT, Hudis CA et al (2015) Trastuzumab interruption and treatment-induced cardiotoxicity in early HER2-positive breast cancer. Breast Cancer Res Treat 149(2):489–495. https://doi.org/10.1007/s10549-014-3253-7 CrossRefPubMedPubMedCentral

Titel: Trastuzumab-induced cardiotoxicity and its risk factors in real-world setting of breast cancer patients
verfasst von: Tiina Moilanen
Anna Jokimäki
Olli Tenhunen
Jussi P. Koivunen
Publikationsdatum: 05.06.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 8/2018
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-018-2682-9

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Springer Medizin

Trastuzumab-induced cardiotoxicity and its risk factors in real-world setting of breast cancer patients

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

Sind Frauen die fähigeren Ärzte?

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2018

Machine learning identifies a core gene set predictive of acquired resistance to EGFR tyrosine kinase inhibitor

Patterns of platinum drug use in an acute care setting: a retrospective study

Tumor growth patterns of MGMT-non-methylated glioblastoma in the randomized GLARIUS trial

End-of-life chemotherapy is associated with poor survival and aggressive care in patients with small cell lung cancer

Loss of EGFR confers acquired resistance to AZD9291 in an EGFR-mutant non-small cell lung cancer cell line with an epithelial–mesenchymal transition phenotype

The value of EBV DNA in early detection of post-transplant lymphoproliferative disorders among solid organ and hematopoietic stem cell transplant recipients

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

Sind Frauen die fähigeren Ärzte?

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Onkologie